Literature DB >> 33733085

The Leptospiral General Secretory Protein D (GspD), a secretin, elicits complement-independent bactericidal antibody against diverse Leptospira species and serovars.

Eja Schuler1, R T Marconi1.   

Abstract

Leptospirosis, the most common zoonotic infection worldwide, is a multi-system disorder affecting the kidney, liver, and lungs. Infections can be asymptomatic, self-limiting or progress to multi-organ system failure and pulmonary hemorrhage. The incidence of canine and human leptospirosis is steadily increasing worldwide. At least sixty-four Leptospira species and several hundred lipopolysaccharide-based serovars have been defined. Preventive vaccines are available for use in veterinary medicine and limited use in humans in some countries. All commercially available vaccines are bacterin formulations that consist of a combination of laboratory cultivated strains of different lipopolysaccharide serotypes. The development of a broadly protective subunit vaccine would represent a significant step forward in efforts to combat leptospirosis in humans, livestock, and companion animals worldwide. Here we investigate the potential of General secretory protein D (GspD; LIC11570), a secretin, to serve as a possible antigen in a multi-valent vaccine formulation. GspD is conserved, expressed in vitro, antigenic during infection and elicits antibody with complement independent bactericidal activity. Importantly, antibody to GspD is bactericidal against diverse Leptospira species of the P1 subclade. Epitope mapping localized the bactericidal epitopes to the N-terminal N0 domain of GspD. The data within support further exploration of GspD as a candidate for inclusion in a next generation multi-protein subunit vaccine.
© 2021 Virgina Commonwealth University.

Entities:  

Keywords:  Canine; GspD; Leptospirosis; Secretin; Spirochetes; Type 2 secretion

Year:  2021        PMID: 33733085      PMCID: PMC7941034          DOI: 10.1016/j.jvacx.2021.100089

Source DB:  PubMed          Journal:  Vaccine X        ISSN: 2590-1362


  47 in total

1.  Immuno-informatics based approaches to design a novel multi epitope-based vaccine for immune response reinforcement against Leptospirosis.

Authors:  Majid Validi; Ahmad Karkhah; Vijay Kumar Prajapati; Hamid Reza Nouri
Journal:  Mol Immunol       Date:  2018-11-15       Impact factor: 4.407

2.  Antigenic potential of a recombinant polyvalent DNA vaccine against pathogenic leptospiral infection.

Authors:  Bashiru Garba; Abdul Rani Bahaman; Zunita Zakaria; Siti Khairani Bejo; Abdul Rahim Mutalib; Faruku Bande; Nasiru Suleiman
Journal:  Microb Pathog       Date:  2018-08-21       Impact factor: 3.738

3.  Incidence rates and risk factors for owner-reported adverse events following vaccination of dogs that did or did not receive a Leptospira vaccine.

Authors:  Peng Ju Yao; Nicole Stephenson; Janet E Foley; Chuck R Toussieng; Thomas B Farver; Jane E Sykes; Katryna A Fleer
Journal:  J Am Vet Med Assoc       Date:  2015-11-15       Impact factor: 1.936

4.  SignalP 5.0 improves signal peptide predictions using deep neural networks.

Authors:  José Juan Almagro Armenteros; Konstantinos D Tsirigos; Casper Kaae Sønderby; Thomas Nordahl Petersen; Ole Winther; Søren Brunak; Gunnar von Heijne; Henrik Nielsen
Journal:  Nat Biotechnol       Date:  2019-02-18       Impact factor: 54.908

5.  Recombinant BCG strains expressing chimeric proteins derived from Leptospira protect hamsters against leptospirosis.

Authors:  Thaís Larré Oliveira; Caroline Rizzi; Carlos Eduardo Pouey da Cunha; Jessica Dorneles; Amilton Clair Pinto Seixas Neto; Marta Gonçalves Amaral; Daiane Drawanz Hartwig; Odir Antônio Dellagostin
Journal:  Vaccine       Date:  2019-01-07       Impact factor: 3.641

6.  Evaluation of different strategies to promote a protective immune response against leptospirosis using a recombinant LigA and LigB chimera.

Authors:  Carlos Eduardo Pouey da Cunha; Everton Burlamarque Bettin; Aisha Farid Abdel Aziz Yousef Bakry; Amilton Clair Pinto Seixas Neto; Marta Gonçalves Amaral; Odir Antonio Dellagostin
Journal:  Vaccine       Date:  2019-02-28       Impact factor: 3.641

7.  Hotspots of canine leptospirosis in the United States of America.

Authors:  Allison M White; Carlos Zambrana-Torrelio; Toph Allen; Melinda K Rostal; Andrea K Wright; Eileen C Ball; Peter Daszak; William B Karesh
Journal:  Vet J       Date:  2017-03-02       Impact factor: 2.688

8.  Clinical, serological and echocardiographic examination of healthy field dogs before and after vaccination with a commercial tetravalent leptospirosis vaccine.

Authors:  Andrea M Spiri; Sabrina Rodriguez-Campos; José M Matos; Tony M Glaus; Barbara Riond; Claudia E Reusch; Regina Hofmann-Lehmann; Barbara Willi
Journal:  BMC Vet Res       Date:  2017-05-25       Impact factor: 2.741

9.  Extended low-resolution structure of a Leptospira antigen offers high bactericidal antibody accessibility amenable to vaccine design.

Authors:  Ching-Lin Hsieh; Christopher P Ptak; Andrew Tseng; Igor Massahiro de Souza Suguiura; Sean P McDonough; Tepyuda Sritrakul; Ting Li; Yi-Pin Lin; Richard E Gillilan; Robert E Oswald; Yung-Fu Chang
Journal:  Elife       Date:  2017-12-06       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.